Loading

logo

Archives of Clinical and Experimental Ophthalmology

ISSN: 2692-4331

Commentary Open Access
Volume 7 | Issue 1 | DOI: https://doi.org/10.46439/ophthalmology.7.040

Non-human primate models and multimodal technologies synergistically drive translational breakthroughs in gene therapy for optic nerve diseases

Jian Wu1,*
  • 1Henan Academy of Innovations in Medical Science, Zhengzhou Aviation Port Economic Zone, No. 1, Bio- Technology Street, Henan, 450008 China
+ Affiliations - Affiliations

Corresponding Author

Jian Wu, karena.wu@foxmail.com

Received Date: May 21, 2024

Accepted Date: June 25, 2025

Citation:

Wu J. Non-human primate models and multimodal technologies synergistically drive translational breakthroughs in gene therapy for optic nerve diseases. Arch Clin Exp Ophthalmol. 2025;7(1):21-24.


Copyright: © 2025 Wu J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

This commentary systematically examines the pivotal role of non-human primate (NHP) models in advancing gene therapy for optic nerve diseases, alongside the ethical and practical challenges they face. It highlights how synergistic innovations in artificial intelligence (AI), organoid technology, CRISPR-based gene editing, and novel delivery systems are reshaping translational paradigms. NHPs, with their anatomical and functional parallels to human visual systems, serve as a gold-standard models for evaluating therapeutic safety, delivery optimization, and long-term efficacy, enabling breakthroughs in treating conditions such as Leber congenital amaurosis (LCA) and non-arteritic anterior ischemic optic neuropathy (NAION). Despite ethical controversies, prolonged experimental timelines, and interspecies variability, AI-driven virtual screening, physiologically relevant organoid models, and non-viral nanocarriers are reducing reliance on NHPs while enhancing therapeutic precision. The review proposes future directions focusing on adeno-associated virus (AAV) vector refinement, multimodal data integration, and interdisciplinary collaboration to accelerate the translation of neuroregenerative therapies for irreversible vision loss.

Keywords

NHPs, Optic neuropathies, Gene therapy, AAV, Retinal organoids

Recommended Articles

The significance of triple-capsid-mutant AAV8 for treatment of Sanfilippo Syndrome Type B

Sanfilippo Syndrome Type-B remains an untreatable childhood neurodegenerative disease with great burden for both patient and caregiver. Very few clinical trials have been undertaken to treat the disease, and none of these have yet yielded clinically obtainable products for patients. Caused by a simple enzyme function deficiency, Sanfilippo Syndrome Type-B has been considered a great prospect for gene-therapy interventions.

Parkinson’s disease: cell therapy vs. gene therapy

Parkinson’s disease (PD) is the second most common neurodegenerative disease, manifesting as a characteristic movement disorder with a number of additional non-motor features. The pathological hallmark of PD is the presence of intra-neuronal aggregates of a-synuclein (Lewy bodies). The movement disorder of PD occurs largely due to loss of dopaminergic neurons of the substantia nigra, resulting in striatal dopamine depletion.

Non-human primate models and multimodal technologies synergistically drive translational breakthroughs in gene therapy for optic nerve diseases

This commentary systematically examines the pivotal role of non-human primate (NHP) models in advancing gene therapy for optic nerve diseases, alongside the ethical and practical challenges they face. It highlights how synergistic innovations in artificial intelligence (AI), organoid technology, CRISPR-based gene editing, and novel delivery systems are reshaping translational paradigms.

Full Text
Cite
Download PDF
Author Information X